All In MedTech

Device Trial Radar · NCT05549232

Hypoxic Red Blood Cells for Burns and Hematological Malignancies at Haukeland University Hospital

A Single Center, Pilot Clinical Investigation of Surgical Bleeding in Burn Patients, and Chronically Transfused Patients With Haematologic Malignancies, Who Are Transfused With Hypoxic Red Blood Cells Manufactured With Hemanext ONE System

Last checked: Nov 20, 2026Latest source record: Jul 23, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

22

Actual

Start

Aug 24, 2022

Primary completion

May 16, 2024

Study completion May 16, 2024

Sponsor

Lead sponsor
HemanextNot on our public-company list
Sponsor type
Industry
First posted
Sep 22, 2022

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The overall objective of this study is to collect preliminary safety data on the transfusion of hypoxic RBCs, manufactured with the Hemanext ONE device, in patients with burns and patients with hematological malignancies. The Hemanext ONE device received CE mark in April 2021.

Conditions

  • Hematologic Neoplasms
  • Burns

Interventions

  • Hypoxic Red Blood CellsDevice

    Hypoxic Red Blood Cells manufactured with the Hemanext ONE device- CPD/PAGGSM Red Blood Cells, Leukocytes Reduced, and O2/CO2 Reduced

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Who Experienced an Adverse Event (All Types/Grades) Within a Time Frame up to 24 Hours Following the Transfusion.Time frame: 24 hours
  2. Number of Participants Who Experienced an Adverse Event (AE) (All Types/Grades) Overall up to 7 Days (+/-1 Day) After the Transfusion.Time frame: 7 days (+/-1 day)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Haukeland University Hospital

    Bergen, Norway

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.